ALMS

Alumis Inc

Add to Watchlist

Advanced Chart

4.640

-0.06(-1.277%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.7629

Open

4.750

VWAP

4.65

Vol

325.19K

Mkt Cap

482.86M

Low

4.570

Amount

1.51M

EV/EBITDA(TTM)

Total Shares

103.19M

2.78M

EV/OCF(TTM)

P/S(TTM)

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

6 Analyst Rating

Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 18.20 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.640

Low

14.00

Averages

18.20

High

22.00

Current: 4.640

Low

14.00

Averages

18.20

High

22.00

Wells Fargo

Derek Archila

Overweight

initiated

$17

2025-07-25

Reason

Wells Fargo

Derek Archila

Price Target

$17

2025-07-25

initiated

Overweight

Reason

Wells Fargo analyst Derek Archila initiated coverage of Alumis with an Overweight rating and $17 price target. The firm says the bull case on the shares centers around A-005 in multiple sclerosis and ESK-001's opportunity in systemic lupus erythematosus.

Guggenheim

Yatin Suneja

initiated

$18

2025-06-10

Reason

Guggenheim

Yatin Suneja

Price Target

$18

2025-06-10

initiated

Reason

Guggenheim analyst Yatin Suneja resumed coverage of Alumis with a Buy rating and $18 price target with the merger with Acelyrin completed. The firm, which highlights the two recent milestones of the announcement of the 52-week Phase 2 OLE data for ESK-001 in psoriasis in March and the completion of Phase 3 ONWARD trials patient enrollment, updated its model to reflect the new share count and cash position post-Acelyrin merger.

Morgan Stanley

NULL -> Overweight

initiated

$23

2025-06-01

Reason

Morgan Stanley

Price Target

$23

2025-06-01

initiated

NULL -> Overweight

Reason

Morgan Stanley resumed coverage of Alumis with an Overweight rating and $23 price target. The firm updated its model for the Acelyrin merger and Q1 earnings. The Phase 3 data from Alumis' lead pipeline program ESK-001 in psoriasis in Q1 of 2026 represents the next key catalyst for the shares, the analyst tells investors in a research note. Morgan believes the company's pipeline is on track.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Maintains

$15 → $14

2025-04-22

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15 → $14

2025-04-22

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$15

2025-03-26

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15

2025-03-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$19 → $15

2025-03-20

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$19 → $15

2025-03-20

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alumis Inc (ALMS.O) is -1.38, compared to its 5-year average forward P/E of -1.47. For a more detailed relative valuation and DCF analysis to assess Alumis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.47

Current PE

-1.38

Overvalued PE

-1.12

Undervalued PE

-1.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.46

Current EV/EBITDA

-0.14

Overvalued EV/EBITDA

0.38

Undervalued EV/EBITDA

-3.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.50

Current PS

36.27

Overvalued PS

43.75

Undervalued PS

-14.75

Financials

Annual

Quarterly

FY2025Q2

2.67M

Total Revenue

FY2025Q2

YoY :

+150.34%

-140.54M

Operating Profit

FY2025Q2

YoY :

-204.98%

59.32M

Net Income after Tax

FY2025Q2

YoY :

-170.64%

0.77

EPS - Diluted

FY2025Q2

YoY :

+102.91%

-106.97M

Free Cash Flow

FY2025Q2

100.00

Gross Profit Margin - %

FY2025Q2

2.23K

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 805.09% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

2.3M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

1.0

Volume

Months

0-12

1.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 805.09% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

2.3M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALMS News & Events

Events Timeline

2025-08-13 (ET)

2025-08-13

16:23:04

Alumis reports Q2 revenue $2.67M, consensus $2.43M

2025-07-24 (ET)

2025-07-24

07:36:58

Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001

2025-07-14 (ET)

2025-07-14

16:10:49

Alumis promotes Sanam Pangali to chief legal officer

News

9.5

08-13NASDAQ.COM

Alumis Misses Q2 Revenue as Costs Jump

9.0

07-24Newsfilter

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

8.5

07-03SeekingAlpha

Alumis files $400M mixed securities shelf